Sugammadex

Overview

Sugammadex is a oligosaccharide active pharmaceutical ingredient (ChEMBL CHEMBL2111107).

API suppliers (3)

Suppliers of Sugammadex backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• RUYUAN HEC PHARM CO LTD1 active DMF
• BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTDChina1 active DMF
• YANGTZE RIVER PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOGICAL PHARMACEUTICAL CO LTDChina1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (7 approved US products), the latest listed US patent on Sugammadex expires 27 Jul 2026 and exclusivity 12 Jun 2028. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

3-[[(1S,3S,5S,6S,8S,10S,11S,13S,15S,16S,18S,20S,21S,23S,25S,26S,28S,30S,31S,33S,35S,36S,38S,40S,41R,43R,44R,45R,46R,47R,48R,49R,50R,51R,52R,53R,54R,55R,56R)-10,15,20,25,30,35,40-heptakis(2-carboxyethylsulfanylmethyl)-41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56-hexadecahydroxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34,37,39-hexadecaoxanonacyclo[36.2.2.23,6.28,11.213,16.218,21.223,26.228,31.233,36]hexapentacontan-5-yl]methylsulfanyl]propanoic acid

Canonical SMILES

C(CSC[C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H](C([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8O)O)O[C@@H]9[C@H](O[C@H](O2)[C@@H]([C@H]9O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)O)O)C(=O)O

InChIKey

WHRODDIHRRDWEW-ZWYCLXBASA-N